BELLICUM PHARMACEUTICALS INC's ticker is BLCM and the CUSIP is 079481107. A total of 102 filers reported holding BELLICUM PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.33 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $6,000 | +20.0% | 5,000 | 0.0% | 0.00% | – |
| Q3 2019 | $5,000 | -58.3% | 5,000 | -23.2% | 0.00% | – |
| Q2 2019 | $12,000 | +140.0% | 6,509 | +331.3% | 0.00% | – |
| Q1 2019 | $5,000 | 0.0% | 1,509 | -24.9% | 0.00% | – |
| Q4 2018 | $5,000 | -82.8% | 2,009 | -57.6% | 0.00% | – |
| Q3 2018 | $29,000 | -67.4% | 4,735 | -60.7% | 0.00% | – |
| Q2 2018 | $89,000 | +89.4% | 12,058 | +66.0% | 0.00% | – |
| Q1 2018 | $47,000 | +38.2% | 7,262 | +79.0% | 0.00% | – |
| Q4 2017 | $34,000 | -22.7% | 4,058 | +5.0% | 0.00% | – |
| Q3 2017 | $44,000 | +131.6% | 3,866 | +135.7% | 0.00% | – |
| Q2 2017 | $19,000 | -32.1% | 1,640 | -25.6% | 0.00% | – |
| Q1 2017 | $28,000 | – | 2,204 | +10920.0% | 0.00% | – |
| Q4 2016 | $0 | -100.0% | 20 | -89.9% | 0.00% | – |
| Q3 2016 | $4,000 | -85.2% | 198 | -89.1% | 0.00% | – |
| Q3 2015 | $27,000 | +145.5% | 1,823 | +261.0% | 0.00% | – |
| Q2 2015 | $11,000 | +120.0% | 505 | +151.2% | 0.00% | – |
| Q1 2015 | $5,000 | – | 201 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Virtus ETF Advisers LLC | 15,086 | $306,000 | 0.84% |
| Baker Brothers Advisors | 4,865,647 | $98,627,000 | 0.82% |
| Cormorant Asset Management, LP | 300,000 | $6,081,000 | 0.73% |
| SPHERA FUNDS MANAGEMENT LTD. | 231,515 | $4,693,000 | 0.69% |
| QVT Financial LP | 340,986 | $6,912,000 | 0.39% |
| Graticule Asia Macro Advisors LLC | 87,000 | $1,763,000 | 0.29% |
| Hatteras Investment Partners, LP | 10,410 | $211,000 | 0.28% |
| MCDANIEL TERRY & CO | 33,836 | $686,000 | 0.18% |
| Highlander Capital Management, LLC | 6,500 | $132,000 | 0.12% |
| EverPoint Asset Management, LLC | 265,000 | $5,372,000 | 0.11% |